https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/rtgpwexe/cover_janfeb25.jpg
Ophthalmology Management
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/dvsf1uun/cover.jpg
Contact Lens Spectrum
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/npjdtl1w/cp_november_cover.jpg
Corneal Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/i5xfuxqu/eb_0125_janfeb-cover.jpg
Eyecare Business
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/i1udssrm/gp_cover_nov24.jpg
Glaucoma Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/mvqdq2hc/nrp_cover_october_2024.jpg
New Retinal Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/1hxbzi3g/op_0125_cover.jpg
Ophthalmic Professional
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/53bbqpwy/screenshot-2024-12-16-at-11437-pm.png
Optometric Management
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/aqbjxwjw/pp-cover.jpg
Presbyopia Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://retinalphysician.com/media/cdbhnbx2/cover_janfeb25_web.jpg
Retinal Physician
Thursday, December 26, 2024
Ocugen, Inc. announced that the data and safety monitoring board (DSMB) for the ArMaDa clinical trial of OCU410 has reviewed interim safety data and approved the continuation of phase 2 of the trial.
Wednesday, December 18, 2024
EyeDNA’s investigational gene therapy receives the Rare Pediatric Disease designation as a potential treatment for retinitis pigmentosa.
Wednesday, December 18, 2024
The QUASAR trial demonstrates noninferiority in treating macular edema secondary to retinal vein occlusion, with longer intervals between treatments. Regeneron will seek FDA approval in 2025.
Wednesday, December 18, 2024
The German company’s VG801 gene therapy targets Stargardt disease and ABCA4-linked retinal conditions.
Monday, December 16, 2024
Thursday, December 12, 2024
Dr. Do, vice chair of clinical affairs and professor of ophthalmology at the Byers Eye Institute, succeeds Peter K. Kaiser, MD, as editor in chief of the magazine.
Friday, December 6, 2024
The phase 3 trial will evaluate the safety and efficacy of the company’s Duravyu intraocular insert in patients with wet AMD.
Friday, December 6, 2024
The company says the AI-powered fundus camera will be available in the United States and Europe.
Friday, December 6, 2024
The phase 3 trial SOL-1 will evaluate the safety and efficacy of the Axpaxli intravitreal implant as a treatment for wet AMD.
Friday, December 6, 2024
A pilot program in Costa Rica prioritizes early detection and treatment of diabetic retinopathy.
Thursday, December 5, 2024
Wednesday, November 20, 2024
The $4.6 billion deal expands the drug wholesaler’s reach in retinal care.
Tuesday, November 19, 2024
Six-month results from the ArMaDa trial for OCU410, a 1-time therapy delivered via subretinal injection, demonstrated safety and functional vision benefits for GA patients.
Monday, November 18, 2024
Data from the LUNA trial, as well as the OPTIC extension study, show a reduction in anti-VEGF injections along with a favorable safety profile. The company is planning a phase 3 trial for 2025.
Tuesday, November 12, 2024
The first patients have been dosed in the LUGANO trial for wet AMD. The company expects to initiate the LUCIA trial by year-end.
Tuesday, November 12, 2024
The PDUFA date for Neurotech Pharmaceuticals's NT-501 has been pushed to March 2025.
Tuesday, November 12, 2024
The combined company will focus on the development of TH103, an intravitreal treatment being studied for age-related macular degeneration.
Tuesday, November 12, 2024
PulseSight Therapeutics presented positive preclinical results on its transferrin therapy at a European meeting.
Tuesday, November 5, 2024
Japanese drugmaker reports plans to conduct a phase1b/2 study of FLQ-101, a preventative treatment for retinopathy of prematurity, in early 2025.
Tuesday, November 5, 2024
Data from the LIGHTSITE III trial confirmed the safety and efficacy of LumiThera's photobiomodulation device as a treatment for vision loss due to age-related macular degeneration.
Friday, November 1, 2024
Data from the phase 2 VERONA trial show improvement in BCVA and CST over baseline.
Wednesday, October 23, 2024
Patients with late stage dry age-related macular degeneration regained the ability to read and recognize faces after receiving the PRIMA retinal implant.
Wednesday, October 23, 2024
Research presented at AAO shows clinics discard most eye drops long before expiration.
Wednesday, October 23, 2024
The new combined company will focus on gene therapy treatments for inherited retinal diseases.
Friday, October 11, 2024
Following FDA feedback, the company reported that it will submit a BLA in early 2025 for its multicharacteristic opsin MCO-010.
Wednesday, October 9, 2024
In participants who received CLS-AX delivered suprachoroidally, BCVA and ocular anatomy (central subfield thickness) were stable up to 6 months compared to participants who received aflibercept.
Thursday, October 3, 2024
After 2 years unavailable in the US, the corticosteroid is once again on the market.
Thursday, October 3, 2024
FDA grants fast track designation for nonanterior noninfectious uveitis treatment.
Tuesday, September 24, 2024
The trial will compare intravitreal injection of AVD-104 to avacincaptad pegol for treatment of geographic atrophy secondary to age-related macular degeneration.
Monday, September 23, 2024
In early-stage choroidal melanoma patients, suprachoroidal injection of bel-sar shows 80% tumor control and 90% vision preservation.
Monday, September 23, 2024
Data from the SAGA study showed patients with geographic atrophy showed improved visual acuity after 2 years on the oral therapy.
Thursday, September 19, 2024
MYL-1701P proves comparable to reference aflibercept at 52 weeks, according to data from the INSIGHT clinical trial.
Thursday, September 19, 2024
The award, recognizing his innovative research in macular edema, was presented at the EURETINA meeting.
Wednesday, September 18, 2024
The FDA designation advances a potential gene therapy treatment for X-linked retinoschisis.
Wednesday, September 18, 2024
Completion of PPQ campaign for novel wet AMD treatment strengthens path to regulatory approval
Friday, September 13, 2024
Topcon’s Maestro2 becomes the first robotic device available in the United States to offer OCT angiography.
Wednesday, September 11, 2024
The study demonstrated a positive safety profile and met secondary and exploratory endpoints associated with subjective and objective evidence of visual function preservation at 6 months.
Sunday, September 8, 2024
Information provided by the AI-driven platform compares favorably to traditional websites when it comes to patient education about uveitis.
Sunday, September 8, 2024
A recent study finds shorter survival in patients with concurrent CNS and vitreoretinal lymphoma.
Sunday, September 8, 2024
Study suggests that melatonin supplementation may reduce the risk of developing age-related macular degeneration.
Sunday, September 8, 2024
Restoret, a potential first-in-class therapy, to be tested for diabetic macular edema.
Sunday, September 8, 2024
First iPSC-derived therapy for photoreceptor diseases to enter clinical testing.
Sunday, September 8, 2024
Phase 1/2 trial results show significant vision improvement for patients with Leber congenital amaurosis 12 months after therapy.
Friday, September 6, 2024
Medicare beneficiaries may be affected by vulnerability in third-party software.
Friday, August 23, 2024
Indian study finds increased risk for premature babies with low hemoglobin levels.
Tuesday, August 20, 2024
Campaign highlights the importance of retina specialists in combating retinal diseases.
Tuesday, August 20, 2024
OPGx-LCA5 is currently being studied in clinical trial as a treatment for Leber congenital amaurosis.
Tuesday, August 20, 2024
The company's ATSN-201 may provide hope for patients with X-linked retinoschisis.
Tuesday, August 20, 2024
Study reveals a significant decline in postoperative eye infection rates, likely due to improved treatment practices.
Tuesday, August 20, 2024
New study demonstrates potential for intravitreal retinal progenitor cell therapy in mitigating photoreceptor degeneration.
Tuesday, August 13, 2024
Monday, August 12, 2024
First patients dosed in clinical trial for novel corticosteroid implant.
Monday, August 12, 2024
Epiretinal macrophage–like cells could help monitor progression of diabetic retinopathy.
Monday, August 12, 2024
The new device, approved by the FDA earlier this year, delivers Acthar Gel, a uveitis treatment.
Monday, August 12, 2024
The SOL-R trial will evaluate the company's Axitinib implant as a treatment for wet age-related macular degeneration.
Monday, August 12, 2024
Eyedaptic's new Eye6 smart glasses utilize an AI assistant to help patients with daily tasks.
Monday, August 12, 2024
The new code, which will go into effect next year, will facilitate reimbursement for PBM treatment in patients with dry AMD.
Monday, August 12, 2024
Patients treated with Eylea HD showed significant gains in visual acuity, regardless of their baseline BCVA.
Tuesday, July 30, 2024
Post hoc analysis reveals slightly increased MNV incidence with avacincaptad pegol 2 mg, but similar efficacy in geographic atrophy growth reduction regardless of MNV development.
Monday, July 29, 2024
Study reveals enzyme’s role in lysosome dysfunction and drusen formation in age-related macular degeneration.
Monday, July 29, 2024
The Spectralis OCTA module with SHIFT technology reduces acquisition time by 50% while maintaining high image quality.
